Skip to search formSkip to main contentSkip to account menu

AZD1208

Known as: AZD 1208., AZD-1208, pan-PIM Kinase Inhibitor AZD1208 
An orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. Pan-PIM kinase inhibitor AZD1208 inhibits the… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Biphenyl CompoundsThiazolidines
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Next-generation sequencing identifies a novel ELAVL1–TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208
Adriana E. Tron*, Erika K. Keeton*, Minwei Ye, Matias Casas-Selves, Huawei Chen, Keith S. Dillman, Rosemary E. Gale, Chloe… 
2016
2016
Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells
The Pim proteins are Ser/Thr kinases over-expressed in several hematological malignancies such as chronic lymphocytic leukemia… 
2016
2016
Constitutive activation of Pim 1 kinase is a therapeutic target for adult T-cell leukemia
• Epigenetic silencing of miR124a leads to constitutive STAT3 and activation of downstream Pim1. • Pim1 kinase signaling is… 
2016
2016
Abstract CT147: Phase I studies of AZD1208, a PIM kinase inhibitor, in patients with recurrent or refractory acute myelogenous leukemia or advanced solid tumors
AZD1208 is a potent oral ATP-competitive, pan-PIM kinase inhibitor. Here we report the results of 2 Phase 1, open-label, multi… 
2015
2015
FLT3-ITD Confers Resistance to Bortezomib By Protecting the mTOR/4EBP1 Pathway through Activation of STAT5 and Induction of Pim-1 Expression
FLT3-ITD and FLT3-TKD are the most frequent tyrosine kinase mutations in AML, with the former strongly associated with a poor… 
2015
2015
Abstract 5332: The Pim kinase inhibitor AZD1208 sensitizes acute myeloid leukemia cells with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) to cytotoxic effects of chemotherapy…
Purpose: Internal tandem duplication (ITD) in the juxtamembrane domain of the fms-like tyrosine kinase 3 (FLT3) receptor is… 
2014
2014
Abstract 1749: Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies
PIM kinases represent an emerging therapeutic target in multiple hematological malignancies, as exemplified by currently ongoing… 
2014
2014
Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation
Pim kinases have been shown to play a key role as downstream effectors of growth factor signaling in hematological malignancies… 
2014
2014
Abstract 4524: Combined inhibition of PIM and PI3 kinases shows an enhanced efficacy in a number of solid tumour cell lines
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: PIM kinases play an important role in a… 
2011
2011
AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia
Abstract 1540 The PIM serine/threonine kinase family is composed of three highly homologous members; PIM1, PIM2 and PIM3… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)